Precision for Medicine, a leading provider of integrated drug development and commercialization solutions, announced a strategic partnership with SOPHiA GENETICS, a global leader in data-driven medicine. The collaboration aims to enhance biopharma services through the integration of the SOPHiA DDM™ Platform, including its cutting-edge liquid biopsy capabilities, to accelerate biomarker discovery, improve patient stratification, and optimize clinical trial execution.
As part of this alliance, Precision for Medicine will incorporate the SOPHiA DDM™ Platform into its biomarker discovery workflows, clinical trial assays (CTAs), and data analysis solutions. This integration will expand Precision’s ability to support precision medicine strategies across oncology, rare diseases, and genetic disorders—enabling biopharmaceutical companies to advance clinical trials with greater accuracy and efficiency.
Leveraging the SOPHiA DDM™ Platform’s advanced AI and machine learning algorithms, Precision for Medicine will now offer deeper analysis of complex multimodal data—including genomic, radiomic, and clinical datasets. This enriched data interpretation empowers sponsors to identify optimal patient populations for trials, streamline enrollment processes, and improve the development of targeted therapies.
Also Read: PANTHERx® Rare Expands Patient Support Capabilities for Cell and Gene Therapies with RxARECONCIERGE™
Additionally, the globally deployed MSK-ACCESS® powered with SOPHiA DDM™, a sophisticated liquid biopsy assay supported by AstraZeneca, will now be accessible to Precision for Medicine’s biopharma clients. The availability of this next-generation sequencing solution offers invaluable insights through retrospective analysis of clinical trial data—supporting improved patient stratification, trial optimization, and real-world therapeutic assessment.
“We’re thrilled to partner with SOPHiA GENETICS to integrate the SOPHiA DDM™ Platform and integrate MSK-ACCESS® powered with SOPHiA DDM™ into our offering, providing biopharma companies with the tools to accurately identify the right patient populations for enrollment into clinical trials,” said Darren Davis, PhD, Senior Vice President, Precision for Medicine. “By leveraging AI-powered algorithms and machine learning, we can pinpoint biomarkers and genomic signatures that enable more efficient, targeted trials and improve therapeutic efficacy. This ultimately helps speed up patient enrollment, reduce trial costs, and bring therapies to market faster.”
As part of the expanded collaboration, Precision for Medicine will offer a fully integrated service suite—including wet lab testing, data analytics, and clinical trial execution—providing clients with a streamlined, end-to-end solution. This unified approach allows biopharma companies to benefit from seamless support across the entire drug development lifecycle.